Name: Practical Management of Thyroid Cancer. A Multidisciplinary Approach
SKU: 64796018
Price: 126.62 USD
Availability: InStock
Author: Clive Harmer;Ujjal K. Mallick

portada Practical Management of Thyroid Cancer. A Multidisciplinary Approach

Practical Management of Thyroid Cancer. A Multidisciplinary Approach

Formato

Libro Físico

Editorial

Springer International Publishing AG

Autor

Clive Harmer;Ujjal K. Mallick

Año

2025

N° páginas

399

Encuadernación

Tapa Blanda

Dimensiones

25.4x17.8 cm

ISBN13

9783031386077

Practical Management of Thyroid Cancer. A Multidisciplinary Approach

Clive Harmer;Ujjal K. Mallick (Autor) · Springer International Publishing AG · Tapa Blanda

Libro Nuevo Importado

Envío: 20 a 27 días háb.

$ 253.24$ 126.62

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 126.62

Llega entre el 21 Sep y el 02 Oct a Quito, Pichincha. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Practical Management of Thyroid Cancer. A Multidisciplinary Approach"

Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer. It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic. The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed. The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well. This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.